

Lotte M G Steuten

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5118644/publications.pdf>

Version: 2024-02-01

68
papers

2,320
citations

218677

26
h-index

223800

46
g-index

70
all docs

70
docs citations

70
times ranked

3559
citing authors

#	ARTICLE	IF	CITATIONS
1	Towards a Broader Assessment of Value in Vaccines: The BRAVE Way Forward. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 105-117.	2.1	25
2	Delivering precision oncology to patients with cancer. <i>Nature Medicine</i> , 2022, 28, 658-665.	30.7	125
3	Realising the broader value of vaccines in the UK. <i>Vaccine: X</i> , 2021, 8, 100096.	2.1	12
4	Value of Information Analysis for Research Decisions—An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. <i>Value in Health</i> , 2020, 23, 139-150.	0.3	105
5	Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. <i>Value in Health</i> , 2020, 23, 277-286.	0.3	75
6	Treatment Patterns, Overall Survival, and Total Healthcare Costs of Advanced Merkel Cell Carcinoma in the USA. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 733-740.	2.1	7
7	Cost-Effectiveness Analysis of a Procalcitonin-Guided Decision Algorithm for Antibiotic Stewardship Using Real-World U.S. Hospital Data. <i>OMICS A Journal of Integrative Biology</i> , 2019, 23, 508-515.	2.0	33
8	Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 1133-1139.	0.9	11
9	Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States. <i>Thrombosis Research</i> , 2019, 180, 37-42.	1.7	15
10	The cost impact of PCT-guided antibiotic stewardship versus usual care for hospitalised patients with suspected sepsis or lower respiratory tract infections in the US: A health economic model analysis. <i>PLoS ONE</i> , 2019, 14, e0214222.	2.5	23
11	Is Procalcitonin Biomarker-Guided Antibiotic Therapy a Cost-Effective Approach to Reduce Antibiotic Resistant and Clostridium difficile Infections in Hospitalized Patients?. <i>OMICS A Journal of Integrative Biology</i> , 2018, 22, 616-625.	2.0	3
12	Effect of a Low vs Intermediate Tidal Volume Strategy on Ventilator-Free Days in Intensive Care Unit Patients Without ARDS. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1872.	7.4	195
13	Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation. <i>BMC Cancer</i> , 2018, 18, 895.	2.6	17
14	Surveillance magnetic resonance imaging for isolated optic pathway gliomas: is gadolinium necessary?. <i>Pediatric Radiology</i> , 2018, 48, 1472-1484.	2.0	19
15	To Genotype or Phenotype for Drug and Food Safety? Exiting the Technology Echo Chambers. <i>OMICS A Journal of Integrative Biology</i> , 2018, 22, 525-527.	2.0	0
16	(Very) Early technology assessment and translation of predictive biomarkers in breast cancer. <i>Cancer Treatment Reviews</i> , 2017, 52, 117-127.	7.7	13
17	Value of Implementation of Strategies to Increase the Adherence of Health Professionals and Cancer Survivors to Guideline-Based Physical Exercise. <i>Value in Health</i> , 2017, 20, 1336-1344.	0.3	12
18	Procalcitonin Biomarker Algorithm Reduces Antibiotic Prescriptions, Duration of Therapy, and Costs in Chronic Obstructive Pulmonary Disease: A Comparison in the Netherlands, Germany, and the United Kingdom. <i>OMICS A Journal of Integrative Biology</i> , 2017, 21, 232-243.	2.0	8

#	ARTICLE	IF	CITATIONS
19	Uncertainty of Physicians and Patients in Medical Decision Making. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 865-869.	2.0	30
20	A SYSTEMATIC APPROACH FOR ASSESSING, IN THE ABSENCE OF FULL EVIDENCE, WHETHER MULTICOMPONENT INTERVENTIONS CAN BE MORE COST-EFFECTIVE THAN SINGLE COMPONENT INTERVENTIONS. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 444-453.	0.5	1
21	Comparative cost-effectiveness of focal and total salvage 125 I brachytherapy for recurrent prostate cancer after primary radiotherapy. <i>Journal of Contemporary Brachytherapy</i> , 2016, 6, 484-491.	0.9	4
22	Early Stage Health Technology Assessment for Precision Biomarkers in Oral Health and Systems Medicine. <i>OMICS A Journal of Integrative Biology</i> , 2016, 20, 30-35.	2.0	7
23	Commercial viability of medical devices using Headroom and return on investment calculation. <i>Technological Forecasting and Social Change</i> , 2016, 112, 338-346.	11.6	18
24	Economic value of procalcitonin guidance. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1000.	9.1	2
25	Precision Medicine 2.0: The Rise of Glocal Innovation, Superconnectors, and Design Thinking. <i>OMICS A Journal of Integrative Biology</i> , 2016, 20, 493-495.	2.0	4
26	Decisions on Further Research for Predictive Biomarkers of High-Dose Alkylating Chemotherapy in Triple-Negative Breast Cancer: A Value of Information Analysis. <i>Value in Health</i> , 2016, 19, 419-430.	0.3	10
27	Multi-Dimensional Impact of the Publicâ€“Private Center for Translational Molecular Medicine (CTMM) in the Netherlands: Understanding New 21 st Century Institutional Designs to Support Innovation-in-Society. <i>OMICS A Journal of Integrative Biology</i> , 2016, 20, 265-273.	2.0	3
28	A Systematic Review of Health Economic Evaluations of Diagnostic Biomarkers. <i>Applied Health Economics and Health Policy</i> , 2016, 14, 51-65.	2.1	28
29	A cost-effectiveness analysis of using TheraBite in a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 709-718.	1.6	12
30	Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients. <i>PLoS ONE</i> , 2016, 11, e0154386.	2.5	5
31	Development of a web-based tool for the assessment of health and economic outcomes of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA). <i>BMC Medical Informatics and Decision Making</i> , 2015, 15, S4.	3.0	20
32	Return-to-work intervention for cancer survivors: budget impact and allocation of costs and returns in the Netherlands and six major EU-countries. <i>BMC Cancer</i> , 2015, 15, 899.	2.6	15
33	Personalized Dentistry Meets OMICS and â€œOne Healthâ€œ: From Cinderella of Healthcare to Mainstream?. <i>OMICS A Journal of Integrative Biology</i> , 2015, 19, 145-146.	2.0	1
34	Early stage cost-effectiveness analysis of a BRCA1-like test to detect triple negative breast cancers responsive to high dose alkylating chemotherapy. <i>Breast</i> , 2015, 24, 397-405.	2.2	10
35	A PCT algorithm for discontinuation of antibiotic therapy is a cost-effective way to reduce antibiotic exposure in adult intensive care patients with sepsis. <i>Journal of Medical Economics</i> , 2015, 18, 944-953.	2.1	47
36	Therapy for Hematologic Cancers in Older Patients, Quality of Life, and Health Economics. <i>JAMA Oncology</i> , 2015, 1, 571.	7.1	9

#	ARTICLE	IF	CITATIONS
37	Cost-effectiveness of heat and moisture exchangers compared to usual care for pulmonary rehabilitation after total laryngectomy in Poland. <i>European Archives of Oto-Rhino-Laryngology</i> , 2015, 272, 2381-2388.	1.6	14
38	Cost-effectiveness of cognitive behavioral therapy and physical exercise for alleviating treatment-induced menopausal symptoms in breast cancer patients. <i>Journal of Cancer Survivorship</i> , 2015, 9, 126-135.	2.9	33
39	An Appeal to the Global Health Community for a Tripartite Innovation: An "Essential Diagnostics List," "Health in All Policies," and "See-Through 21 st Century Science and Ethics". <i>OMICS A Journal of Integrative Biology</i> , 2015, 19, 435-442.	2.0	14
40	Health Economic Evaluation of a Strict Glucose Control Guideline Implemented Using Point-of-Care Testing in Three Intensive Care Units in The Netherlands. <i>Applied Health Economics and Health Policy</i> , 2015, 13, 399-407.	2.1	3
41	Long-term cost-effectiveness of Oncotype DX [®] versus current clinical practice from a Dutch cost perspective. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 433-445.	1.4	19
42	Improving early cycle economic evaluation of diagnostic technologies. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 491-498.	1.4	19
43	A Call for Pharmacogenovigilance and Rapid Falsification in the Age of Big Data: Why not First Road Test Your Biomarker?. <i>OMICS A Journal of Integrative Biology</i> , 2014, 18, 663-665.	2.0	9
44	Focal salvage iodine-125 brachytherapy for prostate cancer recurrences after primary radiotherapy: A retrospective study regarding toxicity, biochemical outcome and quality of life. <i>Radiotherapy and Oncology</i> , 2014, 112, 77-82.	0.6	85
45	Belief Elicitation to Populate Health Economic Models of Medical Diagnostic Devices in Development. <i>Applied Health Economics and Health Policy</i> , 2014, 12, 327-334.	2.1	16
46	Chronic care management for patients with COPD: a critical review of available evidence. <i>Journal of Evaluation in Clinical Practice</i> , 2013, 19, 734-752.	1.8	40
47	Meta-analysis of the effectiveness of chronic care management for diabetes: investigating heterogeneity in outcomes. <i>Journal of Evaluation in Clinical Practice</i> , 2013, 19, 753-762.	1.8	73
48	A Systematic and Critical Review of the Evolving Methods and Applications of Value of Information in Academia and Practice. <i>Pharmacoeconomics</i> , 2013, 31, 25-48.	3.3	110
49	Cost-Utility of Metal-on-Metal Hip Resurfacing Compared to Conventional Total Hip Replacement in Young Active Patients with Osteoarthritis. <i>Value in Health</i> , 2013, 16, 942-952.	0.3	22
50	Cost-effectiveness analysis of telemonitoring versus usual care in patients with heart failure: The TEHAF study. <i>Journal of Telemedicine and Telecare</i> , 2013, 19, 242-248.	2.7	43
51	Effectiveness of Multidimensional Cancer Survivor Rehabilitation and Cost-Effectiveness of Cancer Rehabilitation in General: A Systematic Review. <i>Oncologist</i> , 2012, 17, 1581-1593.	3.7	109
52	The Effectiveness of Chronic Care Management for Heart Failure: Meta-Regression Analyses to Explain the Heterogeneity in Outcomes. <i>Health Services Research</i> , 2012, 47, 1926-1959.	2.0	71
53	Predicting the health economic performance of new non-fusion surgery in adolescent idiopathic scoliosis. <i>Journal of Orthopaedic Research</i> , 2012, 30, 1453-1458.	2.3	12
54	Early Assessment of Medical Technologies to Inform Product Development and Market Access. <i>Applied Health Economics and Health Policy</i> , 2011, 9, 331-347.	2.1	136

#	ARTICLE	IF	CITATIONS
55	Is it economically viable to employ the nurse practitioner in general practice?. <i>Journal of Clinical Nursing</i> , 2011, 20, 518-529.	3.0	7
56	A cost-effectiveness analysis of a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy. <i>BMC Cancer</i> , 2011, 11, 475.	2.6	39
57	Integrating Health Economics Into the Product Development Cycle. <i>Medical Decision Making</i> , 2011, 31, 596-610.	2.4	37
58	Economic evaluation of nurse practitioners versus GPs in treating common conditions. <i>British Journal of General Practice</i> , 2010, 60, e28-e35.	1.4	48
59	Quality of integrated chronic care measured by patient survey: identification, selection and application of most appropriate instruments. <i>Health Expectations</i> , 2009, 12, 417-429.	2.6	74
60	Analysing uncertainty around costs of innovative medical technologies: The case of fibrin sealant (QUIXILA®) for total knee replacement. <i>Health Policy</i> , 2009, 89, 46-57.	3.0	14
61	How to Move From Belief to Proof? Articulating the Value of Chronic Disease and Care Management Programs for Adults With Asthma. <i>Respiratory Care</i> , 2009, 54, 844-846.	1.6	1
62	Integrating health economics modeling in the product development cycle of medical devices: A Bayesian approach. <i>International Journal of Technology Assessment in Health Care</i> , 2008, 24, 459-464.	0.5	77
63	Transferability of economic evaluations of medical technologies: a new technology for orthopedic surgery. <i>Expert Review of Medical Devices</i> , 2008, 5, 329-336.	2.8	9
64	Health technology assessment of asthma disease management programs. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2007, 7, 242-248.	2.3	9
65	Cost-utility of a disease management program for patients with asthma. <i>International Journal of Technology Assessment in Health Care</i> , 2007, 23, 184-191.	0.5	32
66	COPD as a multicomponent disease: Inventory of dyspnoea, underweight, obesity and fat free mass depletion in primary care. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2006, 15, 84-91.	2.3	145
67	Are we measuring what matters in health technology assessment of disease management? Systematic literature review. <i>International Journal of Technology Assessment in Health Care</i> , 2006, 22, 47-57.	0.5	28
68	Evaluation of a regional disease management programme for patients with asthma or chronic obstructive pulmonary disease. <i>International Journal for Quality in Health Care</i> , 2006, 18, 429-436.	1.8	48